We recently described germline and somatic mutations in the MET gene associated with papillary renal carcinoma type 1. MET mutation M1268T was located in a codon highly conserved among receptor tyrosine kinases, and homologous to the codon mutated in multiple endocrine neoplasia type 2B, and many cases of sporadic medullary carcinoma of the thyroid gland (Ret M918T). Ret M918T and MET M1268T have previously been shown to be highly active in mouse NIH3T3 transformation assays, and to change the substrate speci®city of the kinase. We studied the mechanism of transformation mediated by MET M1268T by analysing a clone, F4, derived from NIH3T3 cells transformed by MET M1268T. In contrast to NIH3T3 cells, F4 cells grew in suspension in tissue culture, and rapidly formed tumors in nude mice. We found that c-Src was constitutively bound to MET proteins in F4 cells, and that Src kinase activity was elevated. Transfection of dominant negative Src constructs into F4 cells eliminated the ability of F4 cells to grow in suspension culture and retarded the growth of F4 cells in vivo. The ability of transfected dominant negative Src constructs to inhibit the growth of F4 cells correlated with the inhibition of phosphorylation of paxillin and focal adhesion kinase. Transfection of dominant negative Src constructs into F4 cells had no eect on Grb2 binding or PLC g phosphorylation. The results suggest that c-Src participates in the tumorigenic phenotype induced in NIH3T3 cells by MET M1268T by signaling through focal adhesion kinase and paxillin.
Introduction
We previously reported that a recently described, inherited form of renal cancer, hereditary papillary renal carcinoma type 1 (HPRC type 1), and a subset of sporadic papillary renal carcinomas were caused by activating mutations in the tyrosine kinase domain of the MET proto-oncogene (Zbar et al., 1994; Zbar and Lerman, 1998; Lubensky et al., 1999) . HPRC type 1, inherited as an autosomal dominant disorder with reduced penetrance, is characterized by a predisposition to develop multiple, bilateral papillary renal neoplasms (Zbar et al., 1994; Lubensky et al., 1999) . Cytogenetic studies have demonstrated trisomy of chromosomes 7 and 17 in both inherited and sporadic papillary renal carcinomas (Kovacs, 1993; Bentz et al., 1996) .
The MET proto-oncogene, a protein receptor tyrosine kinase, is the receptor for hepatocyte growth factor/scatter factor (Bottaro et al., 1991) . This receptor/ligand pair is involved in a wide variety of biologic processes, including muscle and liver formation, cell division, morphogenesis, and neoplasia (Gherardi and Stoker, 1991; Brinkman et al., 1995; Rubin et al., 1993; Jeers et al., 1996) . Usually cell programs are initiated in epithelial cells which express the MET receptor by HGF/SF secreted by mesenchymal cells. The MET gene appears to play a role in the evolution of a number of neoplasms (Di Renzo et al., 1995; Jeers et al., 1996) . Increased MET gene expression has been found in papillary carcinomas of the thyroid gland, carcinomas of the colon, pancreas and ovary, and in osteogenic sarcomas.
Previous studies have identi®ed 15 germline and somatic MET mutations located in 10 codons in the tyrosine kinase domain of the MET protein . Several of the MET mutations (M1268T, D1246 and V11101) were located in codons homologous to codons mutated in other protein receptor tyrosine kinases (Ret M918T, Kit D816V, and c-erbB V1571) . These results suggested that there were speci®c codons within tyrosine kinase domains that when mutated could produce disease, and further that mechanistic studies of mutations in one receptor tyrosine kinase might aord information relevant to mutations in the same codon in other receptor tyrosine kinases. This concept was supported by the observation that introduction of the mutations found in MET into the Ron gene (another receptor tyrosine kinase) led to acquisition of oncogenic potential (Santoro et al., 1998; Williams et al., 1999) .
Previous mechanistic studies of NIH3T3 cells transformed by mutant MET genes have demonstrated that the MET protein was constitutively phosphorylated, and possessed increased kinase activity (Jeers et al., 1997; Bardelli et al, 1998) . Several downstream molecules in the MET signaling pathway were found to be constitutively associated with MET proteins: the multiadaptor protein, GAB1, the Grb2/SOS complex, and the p85 subunit of phosphatidylinositol 3-kinase. Studies have been performed with mutant MET molecules containing both an activating tyrosine kinase mutation and phenylalanine in the place of critical tyrosines (Bardelli et al., 1998; Jeers et al., 1998a; Jeers and Vande Woude, 1999 ). The conclusion from these studies was that mutant MET molecules signal through the same set of signal transducers used by wild-type MET molecules.
Recently, c-Src kinase activity was shown to be essential for HGF-induced motility and anchorageindependent growth of mammary carcinoma cells (Rahimi et al., 1998) . In this report we describe experiments designed to determine whether c-Src was involved in the tumorigenic properties of NIH3T3 cells transformed by MET M1268T. 
Results

Growth
c-Src is constitutively bound to MET proteins and is activated in F4 cells
Previous work established that c-Src bound to wildtype MET and was activated after exposure of wildtype NIH3T3 cells to the ligand HGF/SF (Zhu et al., 1994; Ponzetto et al. 1994) . We tested whether c-Src proteins were constitutively bound to MET proteins, and were activated in F4 cells (Figure 4 ). We precipitated MET proteins from wild-type or F4 cells, and tested for c-Src proteins in the precipitate with anti Src antibody SC-19. Similar amounts of mature MET proteins (p140) were detected in NIH3T3 cells transfected with wild-type MET, F4 cells and NIH3T3 cells transfected with wild-type MET and stimulated with HGF ( Figure 4a ). As we reported previously, NIH3T3 cells transfected with MET mutants (clone F4) showed strong constitutive phosphorylation (Figure 4b) . We found c-Src proteins in MET immunoprecipitates from F4 cells in the absence of ligand ( Figure  4c ), and in wild-type NIH3T3 cells treated with ligand (10 ng/ml) ( Figure 4c ). The expression levels of c-Src were the same in the three cell lines. (Figure 4d ).
To test whether c-Src proteins were constitutively activated in F4 cells, we measured the kinase activity of c-Src in F4 or wild-type NIH3T3 cells (Figure 4e ). Protein extracts from cells were immunoprecipitated with anti-Src SC-19 and were tested by in vitro kinase assays using enolase as an exogenous substrate. c-Src from F4 cells in the absence of ligand, and wild-type NIH3T3 cells in the presence of ligand showed c-Src kinase activity (Figure 4e ). These results demonstrated that c-Src was constitutively bound to MET proteins and was activated in F4 cells.
Growth of F4 cells transfected with DN Src K295M or Src 251
The results presented above demonstrated that the F4 cells formed foci in vitro and formed tumors in nude mice. To determine whether c-Src played an essential role in these neoplastic properties of F4 cells, we transfected the F4 subline with dominant negative (DN) Src mutants K295M or Src 251, and compared the growth of F4 cells transfected with DN Src genes to the growth of the parent F4 line, and to the growth of the F4 sublines transfected with vector. DN Src K295M contains a missense mutation in the ATP binding site; Src 251 has a complete deletion of the kinase domain. Similar amounts of mature MET proteins were detected in F4 cells and in F4 cells transfected with vector (S1-1, S1-2, S1-3), or DN Src constructs (S2-1, S2-2, S2-3, S3-1) ( Figure 5a ). We detected exogenous Src proteins of the expected size in DN Src F4 subclones S2-1, S2-2, S2-3, and S3-1 (Figure 5b ).
F4 cells transfected with DN Src (subclones S2-1, S2-2, S2-3, and S3-1) remained spindle-shaped during culture, did not form multicellular aggregates, and did not detach from plastic culture dishes to grow in To investigate the eect of activity of DN Src on the tumorigenicity induced by M1268T MET, we injected F4, S1-1, S2-3, and S3-1 lines into nude mice subcutaneously and measured tumor growth ( Figure  3) . Tumors formed at sites of injection of S2-3 (DN Src K295M) and S3-1 (DN Src 251) grew signi®cantly more slowly than tumors formed after injection of F4 cells, or the vector control. The sizes of tumors formed after injection of S2-1 and S3-1 cells were 11 and 19% of the size of tumors formed after injection of parental F4 cells (P=0.0119; Figure 3) .
Comparison of the ability of F4 cells and DN F4 sublines to grow in low (0.5%) serum medium
The results presented above demonstrated that the growth of F4 cells in vivo and the ability of F4 cells to form foci was reduced by transfection with DN Src. We tested whether DN Src constructs reduced the ability of F4 cells to grow in vitro in 0.5 or 10% serum (Figure 2b ). Ten thousand cells were cultured in low serum (0.5%) in 6.5 cm culture dishes, and the number of cells was counted on days 1 ± 4. NIH3T3 cells failed to proliferate in low serum medium. F4 cells and DN F4 cells grew in low serum medium; there was no dierence in cell numbers at the various time points. There was no dierence in cell numbers of F4 compared to DN F4 when cells were cultured in 10% serum (Figure 2) .
Effect of DN Src on the constitutive binding of Grb-2 by MET proteins in F4 cells, and on the phosphorylation of PLC g
To determine the basis of the reduction of tumorigenicity in F4 cells mediated by DN Src, we evaluated molecules that function downstream of MET. We immunoprecipitated-MET proteins with anti MET antibody, and tested the immunoprecipitates for the adaptor protein, Grb-2. We detected Grb-2 constitutively bound to MET proteins in F4 cells, and in wild-type NIH3T3 cells stimulated with ligand (10 ng/ml) (Figure 6a ). DN Src had no eect on the binding of Grb-2 (Figure 7d ). We tested for phosphorylation of PLC g in NIH3T3 cells with and without ligand, and in F4 cells (Figure 6c ). We 
MAP kinase is not constitutively activated in F4 cells
We compared the amount of MAP kinase protein and the amount of phosphorylated MAP kinase in F4 cells and in wild-type NIH3T3 cells (Figure 6b ). There was no dierence in the amount of MAP kinase proteins in F4 cells compared to wild-type NIH3T3 cells; there was no constitutive phosphorylation of MAP kinase in F4 cells.
Effect of DN Src on constitutive phosphorylation of paxillin and focal adhesion kinase in F4 cells
We evaluated the eect of DN Src on the phosphorylation of focal adhesion proteins, paxillin, and focal adhesion kinase. We found that paxillin and focal adhesion kinase were constitutively phosphorylated in F4 cells, and that the phosphorylation of paxillin and focal adhesion kinase was dramatically reduced in F4 cells transfected with DN Src (Figure 7a,b) .
Discussion
In this report we have shown that the tumorigenicity of a clone, F4, derived from NIH3T3 cells transfected with MET mutant M1268T, was inhibited by dominant negative Src. Both the ability of F4 cells to form foci in vitro and the ability of F4 cells to form tumors in vivo were inhibited by transfection with DN Src. F4 cells showed constitutive binding and activation of many of the molecules that normally participate in downstream signaling from the MET receptor tyrosine kinase. The molecules constitutively bound by MET in F4 cells included: c-Src, and the adaptor protein, Grb-2. The molecules constitutively phosphorylated in F4 cells included c-Src, PLC-g, paxillin and focal adhesion kinase.
The biochemical pro®le of proteins bound and/or activated by mutant MET in F4 cells facilitated experiments designed to ®nd correlatations between inhibition of focus formation and tumor formation by DN Src. Phosphorylation of paxillin and focal adhesion kinase were dramatically reduced in F4 cells transfected with DN Src. Transfection of DN Src markedly decreased phosphorylation of paxillin and focal adhesion kinase, but did not aect cell growth in low serum medium, constitutive phosphorylation of PLC-g, or binding of Grb-2. These results suggest that the ability of F4 cells to form foci in vitro and form (b) S1-1, S1-2, and S1-3 were F4 transfected with empty vector. S2-1, S2-2 and S2-3 were F4 transfected with Src K295M gene. S3-1 was F4 transfected with Src 251. Src K295M showed a 60 kD product and Src 251 showed a 30 kD product. Anti-avian Src antibody recognized only exogenous Src protein Oncogene Dominant negative Src inhibits bioactivity of M1268T MET N Nakaigawa et al tumors in vivo were dependent, at least in part, on the binding and activation of c-Src. Kaplan et al. (1995) focused attention on the seemingly paradoxical eects of c-Src and v-Src on cellular adhesion. Kaplan et al. (1995) found that c-Src positively in¯uenced cellular adhesion, while v-Src resulted in morphogic transformation and an apparent reduction in cellular adhesion. The authors suggested that dierent levels of kinase activity in the two proteins in focal adhesions might partially explain the paradox. F4 cells, characterized by reduced cellular adhesion and activation of c-Src, may be analogous to v-Src driven transformed ®broblasts. DN Src constructs by interfering with the high degree of c-Src activation may increase cellular adhesion in this context.
Insight into the role of c-Src in tumorigenesis mediated by MET M1268T maybe obtained by considering the results of studies by others on v-Src and c-Src. The majority of the transforming v-Src is located in cytoskeleton and phosphorylates the components of the cytoskeleton (Hamaguchi et al., 1987; Sefton et al., 1981; Pasquale et al., 1986; Gould et al., 1986; Wu et al., 1991; Turner et al., 1990) . Normally, c-Src is associated with inner plasma membrane or with endosomal membrane, not cytoskeleton. It was reported that c-Src was activated and translocated to the cytoskeleton after the stimulation of plateletderived growth factor (PDGF) or epidermal growth factor (EGF) (Oude Weernink et al., 1995) . We demonstrated that phosphorylation of paxillin, and focal adhesion kinase induced by mutant MET is dependent on c-Src activity. Paxillin is a cytoskeletal protein and it has been reported that cell spreading correlated with paxillin phosphorylation. The data suggests that c-Src activated by M1268T MET modi®es the cytoskeleton via phosphorylation of paxillin and focal adhesion kinase leading to focus formation and the rapid growth of tumors.
Materials and methods
Cells and cultures
Transfected NIH3T3 cells (Parental NIH3T3; CRL 1658) were cultured in Dulbecco's Modi®ed Eagle Medium (DMEM) (Life Technologies)/10% calf serum (CS) (Life Technologies), 800 mg/ml Geneticin (G418) (Life Technologies). The methods of transfections and establishment of transfected cell lines were described previously (Jeers et al., 1997) . The monoclonal M1268T MET-expressing cell line (F4) was established from a single focus of NIH3T3 transformed by M1268T MET. Five monoclonal NIH3T3 cell lines expressing high amounts of MET M1268T protein were prepared. All ®ve monoclonal lines that expressed high amounts of MET M1268T protein grew in suspension, similar to F4 cells. Dominant negative Src constructs (K295M and 251) were expressed by HyTCX vector with hygromycin B as a selectable marker. We established clonal cell lines expressing dominant negative Src after hygromycin B selection (200 mg/ ml) (Life Technologies). The pictures of cells in culture were taken on the third day after seeding 1610 6 cells in 10 cm dishes including DMEM/10% CS. The numbers of suspended cells and adherent cells were evaluated on the ®fth day after seeding under the above conditions. Cells negative for trypan blue stain were counted.
Constructs
The wild-type Met expression vector contains the murine Met cDNA in pMB1 and Met mutants were constructed using the QuickChange site-directed mutagenesis kit (Stratagene), (Jeers et al., 1997) . The dominant negative avian Src construct, Src 295 (K295M) lacked the ATP binding site; the Src construct Src 251 was truncated after amino acid 251; Src 251 lacked the entire kinase domain) (Kaplan et al., 1994) .
Immunoprecipitations and Western blotting
Stably transfected cells were harvested after 24 h in serumfree culture. Cells were washed twice with ice cold PhosphateBuered Saline (PBS), lysed in ice cold buer consisting of 20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol, 0.1% or 0% SDS, 0.5% Nonidet P-40, 100 mM sodium¯uoride, 200 mM sodium orthovandate, 1 mM EGTA, 2 mM phenylmethylsulfonyl¯uoride, 1 mg/ml leupeptin and 3 mg/ml aprotinin, and centrifuged (30 min, 48C, 14 500 g). Following quantitation, 800 mg of each cell lysate was pre-cleared with protein A sepharose and then incubated with the antibody of interest and protein A sepharose for 3 h at 48C with rotation. The samples were then washed three times with ice cold buer consisting of 20 mM Tris (pH7.4), 100 mM NaCl, 0.5% Nonidet P-40, and 1 mM EDTA. The samples were subjected to SDS ± PAGE on 8 ± 10% gel, and electrotransferred to Immobilon-P (Millipore). After blocking the membrane with 5% albumin, Western blotting was performed using antibody of interest and detected with ECL detection system (Amersham, Newark, NJ, USA).
Anti-mouse MET antibody SC-162, and anti-Src SC-19 (for endogenous Src detection) antibody were purchased from Santa Cruz Biotechnology, (Santa Cruz, CA, USA). Antiphosphotyrosine antibody and anti-avian Src antibody 05 ± 185 to detect exogenous Src were purchased from Upstate Biotechnology, (Lake Placid, NY, USA). Anti Grb-2 antibody G16720, anti paxillin P13520, and anti focal adhesion kinase F15020 antibodies were purchased from Transduction Laboratories (Cincinnati, Ohio, USA).
Kinase assay c-Src was isolated by IP (anti-Src from Santa Cruz Biotechnology) by the same methods as above. After washing with kinase buer (10 mM Tris pH7.4, 5 mM MgCl 2 ), 2.5 mg of enolase was added to each IP. Kinase reactions were initiated by the addition of ATP to 20 mM (10 mCi/nmol [g-32 P]ATP, Amersham, Newark, NJ, USA), incubated at room temperature for 10 min, and products were resolved on 8% acrylamide gels.
Transfection
Transfections were performed using Lipofectamine according to manufacturer's protocol (Life Technologies, Gaithersburg, MD, USA). 1.0610 5 cells in 35 mm plastic dishes were transfected with 2 mg of DNA. Three days after transfection, cells were split into one 145 mm dish containing DMEM/ 10% CS with 200 mg/ml hygromycin B (Life Technologies, Gaithersburg, MD, USA). The cultures were fed every 4 days. After 2 weeks, the colonies were picked up and split to 100 mm dishes.
In vivo tumorigenicity assay 5610 5 cells were inoculated subcutaneously into 4-week-old female athymic nude mice. Tumors were measured after 2 weeks.
Statistical methods
Data in this study were evaluated using standard analysis of variance (anova), nonparametric methods and simple descriptive techniques. Nonparametric (robust) techniques were used for tumor measurement data. Probability values for dierences among treatment conditions are two-sided unless otherwise stated.
